References
- 1. Bright GM, Melton TW, Rogol AD, Clarke WL. Failure of cortisol blockade to inhibit early morning increases in basal insulin requirements in fasting insulin-dependent diabetics. Diabetes 1980; 29(8):662-4. DOI: 10.2337/diab.29.8.662
- 2. Bolli GB, Gerich JE. The “dawn-phenomenon” a common occurrence in both non-insulindependent and insulin-dependent diabetes mellitus. N Engl J Med. 1984; 310(12):746–50. DOI: 10.1056/NEJM198403223101203
- 3. Shih KC, Hsieh SH, Kwok CF, Hwu CM, Hsieh PS, Ho LT. Effect of growth hormone on dawn phenomenon in patients with type 2 diabetes Growth Factors. 2013;31(2):66-73. DOI: 10.3109/08977194.2013.772996
- 4. Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract. 2005;11(1):55–64. DOI: 10.4158/EP.11.1.55
- 5. Atiea JA, Luzio S, Owens DR. The dawn phenomenon and diabetes control in treated NIDDM and IDDM patients. Diabetes Res Clin Pract 1992;16(3):183–190. Carroll MF, Hardy KJ, Burge MR, Schade DS. Frequency of the dawn phenomenon in type 2 diabetes: implications for diabetes therapy. Diabetes Technol Ther. 2002;4(5):595–605. DOI: 10.1089/152091502320798213
- 6. Campbell PJ, Bolli GB, Cryer PE, Gerich JE. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med. 1985 Jun 6;312(23):1473-9. DOI: 10.1056/NEJM198506063122302
- 7. Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski A. The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care. 1981;4(6):579–85. DOI: 10.2337/diacare.4.6.579
- 8. D’Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab. 2011 Oct;13 Suppl 1:126-32. DOI: 10.1111/j.1463-1326.2011.01449.x
- 9. Monnier L, Colette C, Dejager S, Owens D. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care. 2013;36(12):4057–62. DOI: 10.2337/dc12-2127
- 10. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c independent risk factor for diabetic complications. J Am Med Assoc. 2006;295(14):1707–8. DOI: 10.1001/jama.295.14.1707
- 11. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care. 2009;32(10):1901-3. DOI: 10.2337/dc09-0109
- 12. Frontoni S, Di Bartolo P, Avogaro A, Bosi E, Paolisso G, Ceriello A. Glucose variability: An emerging target for the treatment of diabetes mellitus. Diabetes Res Clin Pract. 2013;102(2):86-95. DOI: 10.1016/j.diabres.2013.09.007
- 13. Xu F, Zhao LH, Su JB, Chen T, Wang XQ, Chen JF, et al. The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetol Metab Syndr. 2014;6(1):139. DOI: 10.1186/1758-5996-6-139
- 14. Smith-Palmer J, Brändle M, Trevisan R, Orsini Federici M, Liabat S, Valentine W. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(3):273-84. DOI: 10.1016/j.diabres.2014.06.007
- 15. Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, de Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation. 1997;96(6):1750–4. DOI: 10.1161/01.CIR.96.6.1750
- 16. Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care. 2005; 28(5):1231-39. DOI: 10.2337/diacare.28.5.1231
- 17. Ward WK, Castle JR, Jacobs PG, Cargill RS. Can glucose be monitored accurately at the site of subcutaneous insulin delivery? J Diabetes Sci Technol. 2014;8(3):568-74. DOI: 10.1177/1932296814522805
- 18. Czerwoniuk D, Fendler W, Walenciak L, Mlynarski W. GlyCulator: a glycemic variability calculation tool for continuous glucose monitoring data. J Diabetes Sci Technol. 2011; 5(2):447–51. DOI: 10.1177/193229681100500236
- 19. Khadilkar KS, Bandgar T, Shivane V, Lila A, Shah N. Current concepts in blood glucose monitoring. Indian J Endocrinol Metab. 2013;17(Suppl 3):S643–9. DOI: 10.4103/2230-8210.123556
- 20. Higuchi T. Approach to an irregular time series on the basis of the fractal theory. Physica D. 1988;31(2):277–83. DOI: 10.1016/0167-2789(88)90081-4
- 21. Monnier L, Colette C, Dejager S, Owens D. The dawn phenomenon in type 2 diabetes: How to assess it in clinicalpractice? Diabetes Metab. 2015;41(2):132-7. DOI: 10.1016/j.diabet.2014.10.002
- 22. Directive 2001/20/CE of the European Parliament and of the council of 4April 2001 on the approximation of the laws, regulations and administrativeprovisions of the Member States relating to the implementation of goodclinical trials on medicinal products for human use. Off J Eur Communities. 2001;L121:33–44.
- 23. Monnier L, Colette C, Sardinoux M, Baptista G, Regnier-Zerbib A, Owens D. Frequency and severity of the dawn phenomenon in type 2 diabetes: relationship to age. Diabetes Care. 2012;35(12):2597-9. DOI: 10.2337/dc12-0385
- 24. Boden G, Chen X, Urbain JL. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes. 1996;45(8):1044–50. DOI: 10.2337/diabetes.45.8.1044 DOI: 10.2337/diab.45.8.1044
- 25. Porcellati F, Lucidi P, Cioli P, Candeloro P, Marinelli Andreoli A, Marzotti S et al. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. Diabetes Care. 2015 Mar;38(3):503-12. DOI: 10.2337/dc14-0649
- 26. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-7. DOI: 10.1001/jama.295.14.1681
- 27. Wójcicki JM. “J”-index. A new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res. 1995;27(1):41–42. DOI: 10.1055/s-2007-979906
- 28. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005;7(2):253–63. DOI: 10.1089/dia.2005.7.253
- 29. Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia. 1972;8(5):342–348. DOI: 10.1007/BF01218495